J&J partners with Kaken on STAT6 program, getting rights to KP-723 oral inhibitor. Kaken receives $30M upfront, potential $1.2B in milestone payments after Phase 1.
BioNTech settles with NIH and UPenn over Comirnaty royalties, paying $750M to NIH and $400M to UPenn for 2020-2023, with ...
WuXi Apptec will sell its Advanced Technologies unit to the US private equity firm Altaris for an undisclosed amount, a ...
Novo Nordisk's CagriSema fell short of weight loss goals, causing 17% stock drop. Drug shows similar results to Eli Lilly's ...
The Centers for Medicare and Medicaid Services on Friday released detailed but heavily redacted explanations of how it ...
The Federal Trade Commission is praising an appeals court decision calling for Teva to delist five inhaler patents from the ...
Amgen, Eli Lilly and UCB sued the federal government, claiming that several STD clinics getting drug discounts under the federal 340B aren’t actually eli ...
Generic drug firm Viatris announced Monday that one of its India-based manufacturing facilities has been placed on import ...
An affiliate of Deerfield Management Company will acquire Singular Genomics Systems, ending a months-long competition between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback